The two-dose vaccine regimen is indicated for use in people aged 18 years and above with specific mpox infection risk factors. Credit: angellodeco / Shutterstock.com.

The Advisory Committee on Immunization Practices of the US Centers for Disease Control and Prevention has recommended the routine usage of Bavarian Nordic’s mpox vaccine, Jynneos, in adults.

The two-dose vaccine regimen is indicated for use in those aged 18 years and above with specific mpox infection risk factors. 

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The committee had previously recommended the use of Jynneos in people at risk of infection only at the time of an outbreak. 

Bavarian Nordic president and CEO Paul Chaplin stated: “Since the outbreak of mpox last year, Bavarian Nordic has supplied millions of doses of our vaccine to more than 70 countries worldwide, which has had a positive impact on controlling this unprecedented outbreak of mpox. 

“The broadened ACIP recommendation recognises the significance of maintaining a high awareness of the disease among risk groups and the importance of ensuring broader access to the vaccine beyond an outbreak situation.” 

Subject to obtaining approval for the modified recommendations, the company plans to make Jynneos commercially available in the US in the first half of 2024.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Jynneos received FDA approval in 2019.

In August 2023, Bavarian Nordic received a $120m US Biomedical Advanced Research and Development Authority contract to produce smallpox/mpox vaccine in bulk.

In 2022, the Standing Committee for Vaccination in Germany recommended the vaccine use in adults at risk.

The European AIDS Clinical Society subsequently recommended Jynneos use in adult HIV patients, or in those receiving pre-exposure prophylaxis treatment.